1446358-49-1

Basic information

• Product Name: 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• Synonyms: 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole
• CAS NO: 1446358-49-1
• Molecular Weight: 369.33
• Mol File: 1446358-49-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-49-1)
• EPA Substance Registry System: 3-(3-(5-fluoro-4-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole(1446358-49-1)

Safety Data

• Hazardous Substances Data: 1446358-49-1(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 1446358-48-0 3-(3-(4-chloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1330044-12-6 2-ethynyl-5-fluoro-4-methoxypyrimidine 
• 1330044-11-5 5-fluoro-4-methoxy-2-[(trimethylsilyl)ethynyl]pyrimidine 
• 1216246-45-5 (2-fluorobenzyl)hydrazine hydrochloride salt 
• 1446359-44-9 3-(3-(4-chloro-5-fluoro-6-methoxypyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1446359-43-8 3-(3-(4,6-dichloro-5-fluoropyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazol-5-yl)isoxazole 
• 1354041-91-0 5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)-pyrimidin-4-ol 
• 124-41-4 sodium methylate 
• 1354044-23-7 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide 
• 1354044-05-5 1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazole-3-carboximidamide hydrochloride 
• 1446353-66-7 C₁₄H₉FN₄O 
• 1446353-53-2 C₁₄H₁₀FN₃O₃ 

Downstream Products

• 1354041-91-0 5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)-pyrimidin-4-ol 

Relevant articles and documents

Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator

Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathw

SOLID DISPERSIONS COMPRISING A SGC STIMULATOR

The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.

2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS

2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.